LifeStance Q1 rev +42% to $203.1M, net loss $62.3M on stock comp; reaffirms FY guidance

LifeStance Health Group, Inc.

Revenue $203.1M (+42% YoY); net loss $62.3M (vs. $8.7M loss) driven by $59.9M stock-based comp.
Adjusted EBITDA flat at $12.5M; Center Margin $54.2M (26.7% of rev, down from 30.7%).
Total clinicians 4,989 (+51% YoY), net add of 199 in Q1; two acquisitions and 41 de novo centers.
New $350M credit facility: $200M term loan, $100M delayed draw, $50M revolver; matures 2027-2028.
Q2 2022 guidance: rev $209-214M, Center Margin $57-61M, Adj. EBITDA $12-15M; full-year reaffirmed.

item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.